Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6PCE3

UPID:
PGM2L_HUMAN

ALTERNATIVE NAMES:
PMMLP; Phosphoglucomutase-2-like 1

ALTERNATIVE UPACC:
Q6PCE3; Q96MQ7; Q9UIK3

BACKGROUND:
The enzyme Glucose 1,6-bisphosphate synthase, with alternative names PMMLP and Phosphoglucomutase-2-like 1, is essential for glucose metabolism. It utilizes 1,3-bisphosphoglycerate to produce glucose 1,6-bisphosphate, facilitating the processing of several 1-phosphate sugars. Its activities, although primarily focused on glucose metabolism, suggest a broader role in cellular physiology.

THERAPEUTIC SIGNIFICANCE:
Associated with a severe neurodevelopmental disorder, the enzyme's dysfunction underscores its importance in human health. Exploring the functions of Glucose 1,6-bisphosphate synthase offers promising avenues for developing treatments for related genetic conditions, emphasizing its therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.